source
- Ultragenyx's Angelman syndrome drug fails Phase 3 trial, halting developmentUltragenyx reported that its experimental antisense oligonucleotide designed for Angelman syndrome did not meet primary endpoints in a Phase 3 study. The trial, which enrolled patients with the ra…
- Pfizer grants Medicus co-development rights to CD228-targeted ADC PF-08046031Pfizer announced it is transferring co-development rights for its CD228-targeted antibody-drug conjugate, PF-08046031, to Medicus Pharma. The ADC, originally discovered by Seagen, will now be adva…